182 related articles for article (PubMed ID: 33278771)
1. Dabrafenib-trametinib combination therapy re-challenge in advanced BRAF
Kashizaki F; Tanaka A; Hattori S; Sugimoto S
Eur J Cancer; 2021 Jan; 143():31-32. PubMed ID: 33278771
[No Abstract] [Full Text] [Related]
2. Dabrafenib plus trametinib in patients with previously untreated BRAF
Planchard D; Smit EF; Groen HJM; Mazieres J; Besse B; Helland Å; Giannone V; D'Amelio AM; Zhang P; Mookerjee B; Johnson BE
Lancet Oncol; 2017 Oct; 18(10):1307-1316. PubMed ID: 28919011
[TBL] [Abstract][Full Text] [Related]
3. Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience.
Khunger A; Khunger M; Velcheti V
Ther Adv Respir Dis; 2018; 12():1753466618767611. PubMed ID: 29595366
[TBL] [Abstract][Full Text] [Related]
4. Dabrafenib and trametinib for the treatment of non-small cell lung cancer.
Kelly RJ
Expert Rev Anticancer Ther; 2018 Nov; 18(11):1063-1068. PubMed ID: 30198802
[TBL] [Abstract][Full Text] [Related]
5. Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report.
Adachi Y; Yanagimura N; Suzuki C; Ootani S; Tanimoto A; Nishiyama A; Yamashita K; Ohtsubo K; Takeuchi S; Yano S
BMC Cancer; 2020 Feb; 20(1):156. PubMed ID: 32093631
[TBL] [Abstract][Full Text] [Related]
6. FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring
Odogwu L; Mathieu L; Blumenthal G; Larkins E; Goldberg KB; Griffin N; Bijwaard K; Lee EY; Philip R; Jiang X; Rodriguez L; McKee AE; Keegan P; Pazdur R
Oncologist; 2018 Jun; 23(6):740-745. PubMed ID: 29438093
[TBL] [Abstract][Full Text] [Related]
7. Adverse Event Management in Patients with
Chalmers A; Cannon L; Akerley W
Oncologist; 2019 Jul; 24(7):963-972. PubMed ID: 30598499
[TBL] [Abstract][Full Text] [Related]
8. BRAF V600E Mediates Crizotinib Resistance and Responds to Dabrafenib and Trametinib in a ROS1-Rearranged Non-Small Cell Lung Cancer: A Case Report.
Li J; Wang Q; Ge J; Tian Y; Yao W
Oncologist; 2021 Dec; 26(12):e2115-e2119. PubMed ID: 34516041
[TBL] [Abstract][Full Text] [Related]
9. Durable Response to Combination of Dabrafenib and Trametinib in BRAF V600E-Mutated Non-small-cell Lung Cancer.
Pervere LM; Rakshit S; Schrock AB; Miller VA; Ali SM; Velcheti V
Clin Lung Cancer; 2017 May; 18(3):e211-e213. PubMed ID: 28024926
[No Abstract] [Full Text] [Related]
10. Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation.
Meng P; Koopman B; Kok K; Ter Elst A; Schuuring E; van Kempen LC; Timens W; Hiltermann TJN; Groen HJM; van den Berg A; van der Wekken AJ
Lung Cancer; 2020 Aug; 146():358-361. PubMed ID: 32534795
[TBL] [Abstract][Full Text] [Related]
11. Gastrointestinal perforation following dabrafenib and trametinib administration in non-small cell lung carcinoma with BRAF V600E mutation: a case report and literature review.
Shimada Y; Sato Y; Tachikawa R; Hara S; Tomii K
Invest New Drugs; 2021 Dec; 39(6):1702-1706. PubMed ID: 34023984
[TBL] [Abstract][Full Text] [Related]
12. Dabrafenib Plus Trametinib for BRAF V600E-Mutant Non-small Cell Lung Cancer: A Patient Case Report.
Pan J
Clin Drug Investig; 2019 Oct; 39(10):1003-1007. PubMed ID: 31250402
[TBL] [Abstract][Full Text] [Related]
13. Dabrafenib Active in Rare NSCLC Subtype.
Cancer Discov; 2016 Jul; 6(7):OF4. PubMed ID: 27207893
[TBL] [Abstract][Full Text] [Related]
14. Response to Dabrafenib Plus Trametinib in a Patient With an Uncommon Activating BRAF Mutation: A First in Non-Small Cell Lung Cancer.
Sharp JA; Jones D; Rotow JK; Fidias PM; Bertino E; Owen DH
J Natl Compr Canc Netw; 2024 Mar; 22(3):. PubMed ID: 38479107
[TBL] [Abstract][Full Text] [Related]
15. Sensitivity to dabrafenib and trametinib treatments in patients with non-small-cell cancer harboring BRAF compound mutations: A pooled analysis of BRAF p.V600E-positive advanced non-small-cell lung cancer.
Seto K; Shimizu J; Masago K; Araki M; Katayama R; Sagae Y; Fujita S; Horio Y; Sasaki E; Kuroda H; Okubo K; Okuno Y; Hida T
Cancer Genet; 2022 Aug; 266-267():1-6. PubMed ID: 35598548
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of BRAF Inhibitors With or Without MEK Inhibitors in BRAF-Mutant Advanced Non-Small-Cell Lung Cancer: Findings From a Real-Life Cohort.
Dudnik E; Bar J; Peled N; Bshara E; Kuznetsov T; Cohen AY; Shochat T; Nechushtan H; Onn A; Agbarya A; Moskovitz M; Keren S; Popovits-Hadar N; Urban D; Mishaeli M; Rabinovich NM; Brenner R; Zer A; Rotem O; Roisman LC; Wollner M;
Clin Lung Cancer; 2019 Jul; 20(4):278-286.e1. PubMed ID: 31060855
[TBL] [Abstract][Full Text] [Related]
17. Exceptionally long-lasting response to dabrafenib plus trametinib treatment in a patient with lung adenocarcinoma harboring the BRAF V600E mutation with high expression of PD-L1: A case report.
Inoue T; Kunimasa K; Tamiya M; Kawamura T; Minami T; Nishino K
Thorac Cancer; 2024 Apr; 15(11):929-933. PubMed ID: 38429896
[TBL] [Abstract][Full Text] [Related]
18. Is time to progression associated with post-progression survival in previously treated metastatic non-small cell lung cancer with BRAF V600E mutation? A secondary analysis of phase II clinical trial data.
Li J; Sasane M; Zhang J; Zhao J; Ricculli ML; Yao Z; Redhu S; Signorovitch J
BMJ Open; 2018 Aug; 8(8):e021642. PubMed ID: 30121602
[TBL] [Abstract][Full Text] [Related]
19. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
Menzies AM; Long GV
Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
[TBL] [Abstract][Full Text] [Related]
20. BRAF/MEK-targeted therapy in BRAF ex15 p.T599dup mutation-driven NSCLC: a case report.
Jiang L; Yang P; Liu Y; Li J
J Cancer Res Clin Oncol; 2024 Mar; 150(3):162. PubMed ID: 38538919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]